Eliassen Strategic Insights
Back to Home

Predictive Opportunities

AI-Powered Market Intelligence

$0M - $0M

Addressable pipeline across 6 high-probability opportunities with time-sensitive buying triggers

0
Opportunities Identified
Q1-Q2
2025 Peak Timing
0
Critical Urgency

Gen AI Production Implementation Wave

Critical Urgency
Q1-Q2 2025$47B by 2025
Position
Advantage

87% of enterprises moving from Gen AI pilots to production deployment. Current failure rate: 63% due to integration, governance, and talent gaps.

Why Eliassen Wins

Eliassen's AI & Data Services practice combines technical implementation expertise with governance frameworks—rare in market. Most competitors offer either strategy consulting OR technical execution, not both.

Actionable Steps

Launch 'Pilot-to-Production' accelerator program with pre-built governance templates
Target companies with stalled AI pilots (identifiable via LinkedIn, tech news)
Create case study library showing 4-6 week pilot-to-production timelines
Partner with LLM vendors (OpenAI, Anthropic) for co-marketing opportunities

Competitive Intelligence

accenture

Leading with myWizard AI platform but $400-600/hr pricing locks out mid-market

deloitte

Strong on strategy, weak on hands-on AI engineering

Eliassen Advantage

Eliassen can deliver equivalent quality at 50-60% cost with faster ramp-up

Real-World Evidence Mandate Expansion

Critical Urgency
Q4 2024 - Q3 2025$8.2B clinical data market
Position
Dominant
Projected Pipeline
8-12 engagements @ $2-5M each (Total: $16-60M pipeline)

FDA expanded RWE requirements for post-market surveillance and label expansions. Top 20 pharma companies must overhaul data infrastructure by end of 2025.

Why Eliassen Wins

Eliassen's Clinical Data Sciences team has rare FDA submission experience + AI/ML chops. Competitors either have regulatory expertise (Deloitte) OR data engineering (tech firms), not both.

Actionable Steps

Host webinar series: 'FDA RWE Playbook for 2025 Label Expansions'
Target VP/SVP Clinical Development at Top 20 pharma (LinkedIn Sales Navigator)
Create RWE maturity assessment tool (lead gen magnet)
Form strategic partnership with healthcare data aggregators (Flatiron Health, Veradigm)

Competitive Intelligence

iqvia

Dominant but slow-moving; 12-18 month implementation cycles

accenture

Strong brand but limited FDA regulatory expertise in data sciences

Eliassen Advantage

Eliassen delivers in 5-7 months with regulatory approval track record

Federal Zero-Trust Architecture Buildout

High Urgency
FY2025-FY2026$22B federal cybersecurity spending
Position
Strong
Projected Pipeline
5-8 agency contracts @ $3-8M each (Total: $15-64M pipeline)

OMB zero-trust mandate has 73% of federal agencies behind schedule. CISA issuing quarterly compliance reports driving urgency.

Why Eliassen Wins

Eliassen Group Federal has cleared consultants + modern ZTA implementation experience. Booz Allen is strong but expensive; smaller firms lack clearances.

Actionable Steps

Target civilian agencies with low OMB maturity scores (public data)
Develop 'Zero-Trust in 90 Days' framework for small-to-mid agencies
Submit proposals for GSA Schedule 70 and SEWP VI vehicles
Showcase DoD ZTA case study in federal marketing materials

Competitive Intelligence

boozAllen

Premium pricing ($250-400/hr) opens door for Eliassen at $180-250/hr

leidos

Strong on infrastructure, weak on modern identity/cloud-native ZTA

Eliassen Advantage

Eliassen offers speed + modern tech stack at competitive pricing

Embedded Insurance Technology Partnerships

Medium-High Urgency
2025-2026$700B by 2030 (25% CAGR)
Position
Emerging
Projected Pipeline
3-5 insurers @ $1.5-4M each (Total: $4.5-20M pipeline)

Traditional insurers partnering with retailers, automakers, fintechs to embed insurance into purchase flows. Technology integration (APIs, data sharing, underwriting automation) is primary barrier.

Why Eliassen Wins

Eliassen has insurance domain knowledge + API/integration capabilities. Market is greenfield—competitors haven't specialized yet.

Actionable Steps

Build 'Embedded Insurance Accelerator' framework (white-label platform)
Target P&C insurers with low digital maturity + partnerships (AM Best ratings + news)
Create thought leadership: 'Embedded Insurance Tech Stack Blueprint'
Recruit 2-3 insurance tech specialists to build credibility

Competitive Intelligence

accenture

Leading on strategy but light on implementation

cognizant

Strong on legacy insurance but weak on modern embedded models

Eliassen Advantage

First-mover advantage in specialized embedded insurance implementation

Basel IV Compliance Surge (Extended Deadline)

High Urgency
Q1 2025 - Q2 2026$18B compliance technology market
Position
Strong
Projected Pipeline
6-10 banks @ $2-6M each (Total: $12-60M pipeline)

Basel IV deadline extended to 2025 but banks warned to accelerate. Mid-tier banks ($10-100B assets) are most behind. Estimated $50-200M compliance cost per institution.

Why Eliassen Wins

Eliassen's Financial Risk & Compliance practice has Basel implementation experience. Big 4 audit conflicts prevent them from serving audit clients on Basel compliance consulting.

Actionable Steps

Target 30 mid-tier banks with low capital adequacy ratios (public filings)
Develop 'Basel IV Readiness Assessment' (3-week engagement, $150-250K)
Partner with fintech vendors (Moody's Analytics, SAS) for joint go-to-market
Publish Basel IV compliance timeline/checklist tool (lead gen)

Competitive Intelligence

deloitte

Audit conflicts limit addressable market to non-audit clients only

pwc

Same audit conflict issue—opens door for Eliassen

Eliassen Advantage

No audit conflicts = can serve 100% of market vs. Big 4's ~60%

Decentralized Clinical Trial Technology

Medium-High Urgency
2025-2027$16B DCT market by 2027
Position
Advantage
Projected Pipeline
4-7 biotech companies @ $2-5M each (Total: $8-35M pipeline)

35% of clinical trials will be decentralized by 2027 (up from 9% in 2023). Requires patient-facing apps, remote monitoring, data integration, regulatory compliance expertise.

Why Eliassen Wins

Eliassen's Clinical Solutions + App Development practices can deliver end-to-end DCT platforms. Most competitors are either tech-focused (no regulatory expertise) or CROs (limited software engineering).

Actionable Steps

Build DCT reference architecture and platform accelerator
Target mid-sized biotech companies running Phase 2/3 trials (clinicaltrials.gov data)
Partner with Medidata, Veeva for co-marketing and technology integration
Create 'DCT Regulatory Playbook' as thought leadership piece

Competitive Intelligence

iqvia

CRO-first mindset, technology is secondary—slower, more expensive

medidata

Software vendor, not full-service implementation partner

Eliassen Advantage

Eliassen bridges tech + regulatory as full-service delivery partner

Market Signals Driving Urgency

87% of enterprises piloting Gen AI (Wall Street Journal, Nov 2024)
Implication: Pilot-to-production services will see 300-400% demand increase in Q1-Q2 2025
Action: Launch Gen AI production accelerator program immediately
FDA RWE guidance expansion (October 2024)
Implication: Top 20 pharma companies will issue RFPs for data platform overhauls by Q1 2025
Action: Pre-emptive outreach to CVP Clinical Development contacts in Q4 2024
Federal IT spending up 4.2% YoY to $115B (IDC, Aug 2024)
Implication: Federal market expansion with focus on cloud, cybersecurity, AI
Action: Increase Eliassen Group Federal sales headcount by 20-30%
Basel IV compliance costs $50-200M per bank (American Banker, Sept 2024)
Implication: Mid-tier banks will prioritize compliance projects over innovation in 2025
Action: Position compliance services as revenue-protection vs. cost-center
Decentralized clinical trials at 35% penetration by 2027 (McKinsey, June 2024)
Implication: DCT technology projects will become standard in 2025-2026 planning cycles
Action: Build DCT capability and platform accelerator in Q4 2024

Threats to Watch

Big 4 pricing pressure on mid-market

Accenture, Deloitte lowering rates for $500M-$2B companies to defend market share

Mitigation Strategy

Emphasize speed-to-value and boutique service over brand; 50-70% cost savings messaging remains potent

Medium Priority

Indian IT services firms (TCS, Wipro) moving upmarket

Offshore providers hiring U.S.-based consultants and targeting quality-sensitive segments

Mitigation Strategy

Position on specialized expertise (Clinical, Federal cleared) where offshore firms lack depth

Medium-High Priority

AI-powered consulting automation

Tools like ChatGPT Enterprise, Deloitte's generative AI reducing need for junior consultants

Mitigation Strategy

Pivot to AI-augmented consulting—use AI to increase consultant productivity 2-3x, not replace them

High Priority

Predictive Timeline

2025 Q1
Gen AI production implementations, Basel IV compliance surge, Federal zero-trust buildout
$85-150M addressable in immediate-urgency projects
2025 Q2-Q4
RWE platform overhauls (pharma), embedded insurance tech partnerships, DCT platform builds
$120-200M addressable across year
2026
AI-powered clinical trial design, quantum-safe cryptography (federal), climate risk modeling (insurance/finserv)
Build POCs and thought leadership in 2025 to dominate 2026